Carnitine palmitoyltransferase II deficiency

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
Carnitine palmitoyltransferase II deficiency
Classification and external resources
Carnitine
ICD-9 277.85
OMIM 255110
DiseasesDB 32534
eMedicine ped/321 

WikiDoc Resources for

Carnitine palmitoyltransferase II deficiency

Articles

Most recent articles on Carnitine palmitoyltransferase II deficiency

Most cited articles on Carnitine palmitoyltransferase II deficiency

Review articles on Carnitine palmitoyltransferase II deficiency

Articles on Carnitine palmitoyltransferase II deficiency in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Carnitine palmitoyltransferase II deficiency

Images of Carnitine palmitoyltransferase II deficiency

Photos of Carnitine palmitoyltransferase II deficiency

Podcasts & MP3s on Carnitine palmitoyltransferase II deficiency

Videos on Carnitine palmitoyltransferase II deficiency

Evidence Based Medicine

Cochrane Collaboration on Carnitine palmitoyltransferase II deficiency

Bandolier on Carnitine palmitoyltransferase II deficiency

TRIP on Carnitine palmitoyltransferase II deficiency

Clinical Trials

Ongoing Trials on Carnitine palmitoyltransferase II deficiency at Clinical Trials.gov

Trial results on Carnitine palmitoyltransferase II deficiency

Clinical Trials on Carnitine palmitoyltransferase II deficiency at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Carnitine palmitoyltransferase II deficiency

NICE Guidance on Carnitine palmitoyltransferase II deficiency

NHS PRODIGY Guidance

FDA on Carnitine palmitoyltransferase II deficiency

CDC on Carnitine palmitoyltransferase II deficiency

Books

Books on Carnitine palmitoyltransferase II deficiency

News

Carnitine palmitoyltransferase II deficiency in the news

Be alerted to news on Carnitine palmitoyltransferase II deficiency

News trends on Carnitine palmitoyltransferase II deficiency

Commentary

Blogs on Carnitine palmitoyltransferase II deficiency

Definitions

Definitions of Carnitine palmitoyltransferase II deficiency

Patient Resources / Community

Patient resources on Carnitine palmitoyltransferase II deficiency

Discussion groups on Carnitine palmitoyltransferase II deficiency

Patient Handouts on Carnitine palmitoyltransferase II deficiency

Directions to Hospitals Treating Carnitine palmitoyltransferase II deficiency

Risk calculators and risk factors for Carnitine palmitoyltransferase II deficiency

Healthcare Provider Resources

Symptoms of Carnitine palmitoyltransferase II deficiency

Causes & Risk Factors for Carnitine palmitoyltransferase II deficiency

Diagnostic studies for Carnitine palmitoyltransferase II deficiency

Treatment of Carnitine palmitoyltransferase II deficiency

Continuing Medical Education (CME)

CME Programs on Carnitine palmitoyltransferase II deficiency

International

Carnitine palmitoyltransferase II deficiency en Espanol

Carnitine palmitoyltransferase II deficiency en Francais

Businness

Carnitine palmitoyltransferase II deficiency in the Marketplace

Patents on Carnitine palmitoyltransferase II deficiency

Experimental / Informatics

List of terms related to Carnitine palmitoyltransferase II deficiency

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch. Carnitine palmitoyltransferase II deficiency is a condition that prevents the body from converting certain fats called long-chain fatty acids into energy, particularly during periods without food. Carnitine, a natural substance acquired mostly through the diet, is used by cells to process fats and produce energy. People with this disorder have a faulty enzyme that prevents these fats from being processed in the mitochondria.

Types

There are three main types of carnitine palmitoyltransferase II deficiency:

  • a lethal neonatal form
  • a severe infantile hepatocardiomuscular form,
  • a myopathic form

Neonatal form

Infants with the lethal neonatal form of this disorder usually experience respiratory failure, liver failure, seizures, and an irregular heart beat leading to cardiac arrest. In many cases, patients have malformed features and an abnormally developed brain and kidneys.

Hepatocardiomuscular type

Signs and symptoms of the infantile hepatocardiomuscular type usually appear between 6 and 24 months of age. This condition involves recurring attacks of abnormally low levels of fat breakdown products and blood sugar (hypoketotic hypoglycemia) causing a loss of consciousness and seizures. Liver failure and an enlarged liver (hepatomegaly) are also sometimes seen. In many cases, there is also heart involvement. Episodes are often triggered by infections, fever, or fasting.

Myopathic form

The myopathic form is the most frequently seen and least severe form of carnitine palmitoyltransferase II deficiency. It has a variable age of onset and is characterized by muscle pain (myalgia) and weakness. This condition is sometimes associated with the abnormal breakdown of an oxygen-binding muscle protein called myoglobin (myoglobinuria). Myoglobinuria can cause kidney failure and death.

Causes

Mutations in the CPT2 gene cause carnitine palmitoyltransferase II deficiency, leading to the production of a defective version of an enzyme called carnitine palmitoyltransferase II.

Without this enzyme, long-chain fatty acids from food and fats stored in the body cannot be broken down and processed.

Excessive levels of long-chain fatty acids may build up in tissues, damaging the heart, liver, and muscles and causing more serious complications.

This condition is inherited in an autosomal recessive pattern.

See also

This article incorporates public domain text from The U.S. National Library of Medicine

fr:Déficit en carnitine palmitoyltransférase II
WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools